The impact of candidate influenza virus and egg-based manufacture on vaccine effectiveness: Literature review and expert consensus.

Vaccine 2020 08 26;38(38):6047-6056. Epub 2020 Jun 26.

Royal College of General Practitioners, British Global and Travel Health Association, London, UK.

Introduction: Influenza is associated with significant morbidity and mortality worldwide. Whilst vaccination is key for the prevention of influenza infection, there are many factors which may contribute to reduced vaccine effectiveness, including antigenic evolution via both antigenic drift and egg-adaptations. Due to the currently dissociated and indirect evidence supporting both the occurrence of these two phenomena in the egg-based manufacturing process and their effects on vaccine effectiveness, this topic remains a subject of debate.

Objective: To review the evidence and level of agreement in expert opinion supporting a mechanistic basis for reduced vaccine effectiveness due to egg-based manufacturing, using an expert consensus-based methodology and literature reviews.

Methods: Ten European influenza specialists were recruited to the expert panel. The overall research question was deconstructed into four component principles, which were examined in series using a novel, online, two-stage assessment of proportional group awareness and consensus. The first stage independently generated a list of supporting references for each component principle via literature searches and expert assessments. In the second stage, a summary of each reference was circulated amongst the experts, who rated their agreement that each reference supported the component principle on a 5-point Likert scale. Finally, the panel were asked if they agreed that, as a whole, the evidence supported a mechanistic basis for reduced vaccine effectiveness due to egg-based manufacturing.

Results: All component principles were reported to have a majority of strong or very strong supporting evidence (70-90%).

Conclusions: On reviewing the evidence for all component principles, experts unanimously agreed that there is a mechanistic basis for reduced vaccine effectiveness resulting from candidate influenza virus variation due to egg-based manufacturing, particularly in the influenza A/H3N2 strain. Experts pointed to surveillance, candidate vaccine virus selection and manufacturing stages involving eggs as the most likely to impact vaccine effectiveness.

Download full-text PDF

http://dx.doi.org/10.1016/j.vaccine.2020.06.021DOI Listing
August 2020
Save 15% Survey

Similar Publications

Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.

Influenza Other Respir Viruses 2012 Mar 8;6(2):142-52, e1-5. Epub 2011 Aug 8.

National Influenza Centre, Accra, Ghana.

• For almost 60 years, the WHO Global Influenza Surveillance and Response System (GISRS) has been the key player in monitoring the evolution and spread of influenza viruses and recommending the strains to be used in human influenza vaccines. The GISRS has also worked to continually monitor and assess the risk posed by potential pandemic viruses and to guide appropriate public health responses. • The expanded and enhanced role of the GISRS following the adoption of the International Health Regulations (2005), recognition of the continuing threat posed by avian H5N1 and the aftermath of the 2009 H1N1 pandemic provide an opportune time to critically review the process by which influenza vaccine viruses are selected. Read More

View Article and Full-Text PDF
March 2012

Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing.

Ther Adv Vaccines Immunother 2020 22;8:2515135520908121. Epub 2020 Feb 22.

Medical Affairs, Americas, Seqirus Inc., Cambridge MA, USA.

Influenza continues to cause severe illness in millions and deaths in hundreds of thousands annually. Vaccines are used to prevent influenza outbreaks, however, the influenza virus mutates and annual vaccination is required for optimal protection. Vaccine effectiveness is also affected by other potential factors such as the human immune system, a mismatch with the chosen candidate virus, and egg adaptation associated with egg-based vaccine production. Read More

View Article and Full-Text PDF
February 2020

Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses.

PLoS One 2014 25;9(3):e92153. Epub 2014 Mar 25.

Influenza and Respiratory Virus Section, National Microbiology Laboratory, Winnipeg, Manitoba, Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.

Background: Influenza vaccine effectiveness (VE) is generally interpreted in the context of vaccine match/mismatch to circulating strains with evolutionary drift in the latter invoked to explain reduced protection. During the 2012-13 season, however, detailed genotypic and phenotypic characterization shows that low VE was instead related to mutations in the egg-adapted H3N2 vaccine strain rather than antigenic drift in circulating viruses.

Methods/findings: Component-specific VE against medically-attended, PCR-confirmed influenza was estimated in Canada by test-negative case-control design. Read More

View Article and Full-Text PDF
January 2015

Antigenic characterization of influenza viruses produced using synthetic DNA and novel backbones.

Vaccine 2016 07 21;34(32):3641-8. Epub 2016 May 21.

Seqirus (previously Novartis Influenza Vaccines), 45 Sidney Street, Cambridge, MA 02139, USA.

The global system for manufacturing seasonal influenza vaccines has been developed to respond to the natural evolution of influenza viruses, but the problem of antigenic mismatch continues to be a challenge in certain years. In some years, mismatches arise naturally due to the antigenic drift of circulating viruses after vaccine strain selection has already been made. In other years, antigenic differences between the vaccine virus and circulating viruses are introduced as part of the current system, which relies on the use of egg-adapted isolates as a starting material for candidate vaccine viruses (CVVs). Read More

View Article and Full-Text PDF
July 2016